LEAD DISCOVERY CENTER GMBH

Their core work

Lead Discovery Center (LDC) is a German drug discovery SME that translates early-stage academic research into validated drug candidates for licensing to pharma and biotech companies. Within H2020, they participate in Marie Skłodowska-Curie training networks focused on chemical biology, computational chemistry, and target-based drug design — contributing industry-grade screening and lead optimization expertise. Their projects span from big data in chemistry and protein-protein interaction stabilization to DNA damage repair mechanisms, reflecting a pipeline-oriented approach to identifying new therapeutic targets.

What they specialise in

How they've shifted over time

In their early H2020 participation (2016), LDC engaged broadly across chemical biology — from computational big data in chemistry (BIGCHEM) to protein-protein interaction drug design (TASPPI) and cell division biology (DivIDe). By 2019, their focus sharpened toward a specific therapeutic target class: DNA helicases and genome maintenance enzymes (AntiHelix), which also became their largest funded project. This trajectory shows a shift from general drug discovery methodology toward target-specific inhibitor programs with clearer translational potential.

LDC is moving toward defined molecular targets in genome stability, suggesting future collaborations will likely involve specific inhibitor development programs rather than general methodology projects.

How they like to work

LDC participates exclusively as a partner — never as coordinator — which is typical for an industry SME in MSCA training networks, where universities usually lead. With 45 unique partners across 13 countries from just 4 projects, they operate in large, diverse academic-industry consortia. This makes them an accessible partner: they are accustomed to working within large multinational teams and providing industry perspective to primarily academic networks.

Despite only four projects, LDC has built a remarkably broad network of 45 partners across 13 countries, reflecting the large consortium sizes typical of MSCA training networks. Their partnerships span major European research nations, connecting them to leading universities and research institutes in chemical biology and life sciences.

What sets them apart

LDC occupies a rare niche as a dedicated translational drug discovery company — bridging the gap between academic target discovery and pharmaceutical development. Unlike university labs, they bring industry-standard compound screening, medicinal chemistry, and lead optimization capabilities. For consortium builders, LDC offers a credible industry partner that understands both academic research culture (via Max Planck origins) and commercial drug development requirements.

Highlights from their portfolio

• AntiHelix
  Largest project by funding (EUR 505K), most recent, and most target-specific — focusing on DNA helicase inhibitors as potential therapeutics for genome instability diseases.
• TASPPI
  Addresses protein-protein interaction stabilisation, one of the most challenging frontiers in modern drug discovery where few companies have deep expertise.
• BIGCHEM
  Demonstrates LDC's investment in computational and big data approaches to chemistry, complementing their wet-lab drug discovery capabilities.